Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jama.294.16.2083 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nucleus pulposus cell-mimicking nanoparticles for cell-specific HIF1A editing to modulate SASP-mediated disc inflammation via autophagy activation.
Acta Biomater
March 2025
Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address:
Traditional methods of plasmid delivery, including viral vectors, lipofection, and electroporation, are widely used for gene editing but have limitations, such as cellular toxicity, limited transfection efficiency in primary cells, and nonspecific side effects. Here, we report the development of nucleus pulposus cell (NPC)-mimicking nanoparticles (HIF1A@NNP) with an NPC membrane as the shell and pcDNA3.1-rHIF1A encapsulated in the core via extrusion.
View Article and Find Full Text PDFAddressing recurrent weight gain after Roux-en-Y gastric bypass: efficacy of a dual surgical approach-short-term results of a single-center cohort study.
Surg Obes Relat Dis
February 2025
Department of Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA. Electronic address:
Background: There is no gold standard for recurrent weight gain following Roux-en-Y gastric bypass (RYGB). Combining jejuno-jejunostomy distalization type 1 (JJD1) and sleeve resection of the gastrojejunostomy and gastric pouch (GJ-P) may be a potential approach for these patients.
Objectives: To describe 1-year perioperative and nutritional outcomes of patients who underwent JJD1 with sleeve resection of the GJ-P.
Hand therapists' usage and perception of technology and telerehabilitation: An online survey study with a qualitative component.
J Hand Ther
March 2025
Schulich School of Medicine and Dentistry, Western University, London, Canada; Department of Surgery, London Health Sciences Centre, London, Canada. Electronic address:
Background: The COVID-19 pandemic prompted a shift in healthcare delivery, necessitating the rapid adoption of technology, including telerehabilitation. This study focused on understanding the current perspectives and experiences of hand therapists in Canada and the United States regarding implementation of telerehabilitation in hand therapy, traditionally reliant on in-person interactions.
Purpose: The study aimed to assess the utilization, perceptions, and barriers of telerehabilitation among hand therapists, providing insights into challenges and opportunities for incorporation into practices.
Background: Musculoskeletal problems, or aromatase inhibitor-associated musculoskeletal syndrome, in the hands and wrists is a known side effect of aromatase inhibitor medication, often prescribed for 5years or more for breast cancer survivors. No studies were found on the effectiveness of hand therapy for breast cancer survivors experiencing aromatase inhibitor-associated musculoskeletal syndrome in the hands and wrists.
Purpose: The primary objective of this study is to determine the effectiveness of hand therapy on reducing hand and wrist pain, improving grip strength, improving upper extremity function, and improving health related quality of life in breast cancer survivors diagnosed with aromatase inhibitor-associated musculoskeletal syndrome in the hands and wrists.
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial.
Clin Lymphoma Myeloma Leuk
February 2025
Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:
Background: In the phase 3 CANDOR trial (NCT03158688), daratumumab added to carfilzomib and dexamethasone (KdD) significantly prolonged progression-free survival relative to carfilzomib and dexamethasone (Kd) alone in previously treated patients with relapsed/refractory multiple myeloma (RRMM).
Materials And Methods: We present a post hoc analysis of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30-item module (EORTC QLQ-C30) and EORTC QLQ Myeloma 20-item module (EORTC QLQ-MY20) patient-reported outcome (PRO) measures from the CANDOR trial.
Results: Median (range) duration of observation for PROs was 18.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!